As our understanding of changes to the neurological system has improved, it has become
clear that patients who have contracted human immunodeficiency virus type 1 (HIV-1) can …

Individuals suffering from human immunodeficiency virus type 1 (HIV‐1) infection suffer from
a wide range of neurological deficits. The most pronounced are the motor and cognitive …

Whilst effective antiretroviral therapy is protective against the more severe forms of HIV-
associated brain disease, there remains a large burden of clinically symptomatic cognitive …

Human immunodeficiency virus type 1 (HIV) infection presently affects more that 40 million
people worldwide, and is associated with central nervous system (CNS) disruption in at least …

Important advances have been made in recent years in identifying the molecular
mechanisms of HIV neuropathogenesis. Defining the pathways leading to HIV dementia has …

Antiretroviral drugs may help prevent neurological decline in individuals with HIV infection
by suppressing viral replication and associated chronic immune activation in the central …

People living with HIV are affected by the chronic consequences of neurocognitive
impairment (NCI) despite antiretroviral therapies that suppress viral replication, improve …

The growing recognition of the burden of neurologic disease associated with HIV infection in
the last decade has led to renewed efforts to characterize the pathophysiology of the virus …

The development of novel antiretroviral treatments has led to a significant turning point in the
fight against HIV. Although therapy leads to virologic suppression and prolonged life …

The importance of HIV cognitive impairment, including HIV associated dementia (HAD) and
minor cognitive/motor disorder, has continued in the era of highly active antiretroviral …